The rising incidence of papillary thyroid microcarcinoma and is completion surgery necessary or not?

Abstract

Papillary thyroid microcarcinoma (PTMC) is defined as a papillary cancer that is 1 cm or less in its maximal diameter. The incidence of thyroid cancer has increased during the past 30 years. The aim of this study is to evaluate the rising incidence of PTMC (papillary thyroid microcarcinoma) and whether is lobectomy enough or not. The data of 462 consecutive patients who underwent thyroidectomy (hemithyroidectomy and total thyroidectomy) at the Hacettepe University Hospitals Department of ENT from 2000 to 2015 were analyzed. Surgical procedure, histopathologic examinations, postoperative complications, follow-up time and mortality were recorded. USG and FNAC were performed on all cases. Of the 344 patients with thyroid malignancy and 118 patients underwent total laryngectomy with thyroidectomy. 364 patients with TT and 98 patients with HT. The first group included 204 patients (Surgery time 2000-2007), 91 of them ( 44.6%) had PTMC. The second group included 258 patients, 192of them (74,4%) had PTMC (p<0.001). 22 Patients with PTMC underwent completion surgery and 40 of them just followed by hemithyroidectomy. There was no recurrence. PTMC has been rising incidence because of ,pathological and radiological, increased awareness and completion surgery is not necessary for all PTMC cases especially incidental PTMC.

Incidental thyroid carcinomas. A retrospective study

“…However, the data resulting from postoperative scintigraphic controls (57.69% of lymph node metastasis detected) gives us the validation of our approach and some authors agree with us (23,(79)(80)(81)(82). On the contrary some Authors do not share this setting (83)(84)(85)(86)(87)(88)(89)(90)(91) and others suggest a stratification of the risk of recurrence based on the presence of BRAF mutation, extrathyroidal extension, lateral neck lymph node metastases, multifocality, TSH levels, molecular markers, high metabolic tumor volume and tumor stage (92)(93)(94)(95)(96)(97)(98)(99)(100)(101)(102).…”

NRXN2 Possesses a Tumor Suppressor Potential via Inhibiting the Growth of Thyroid Cancer Cells

“…In the past 30 years, the global incidence of thyroid cancer (THCA) has increased significantly, mainly due to the increase in papillary thyroid cancer (PTC) [ 1 , 2 ]. THCA is a common endocrine malignant neoplasm, but its prognosis is satisfying [ 3 ].…”